Program
obicetrapib
Also written as “TA-8995”, “Obicetrapib” and “Obicetrapib 10 mg”.
Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Alzheimer Disease · Hyperlipidemias · Atherosclerosis, led by 3 companies.
Drug pageTA-8995: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NewAmsterdam Pharmaits history only | 197 open or running | phase 3since Nov 18, 2021 | Feb 9, 2021 | Nov 2026phase 2 · NCT06496243 |
| Xention | 60 open or running | phase 2since Oct 21, 2013 | Oct 21, 2013 | none ahead |
| Tanabe Pharmaits history only | 20 open or running | phase 1since Jun 4, 2013 | Jun 4, 2013 | none ahead |
Also a collaborator on its studies: Pharma Medica Research and Novum.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Xention only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Oct 21, 2013First study: phase 2 study in DyslipidemiasFirst studyNCT01970215 · 364 enrolled · Denmark, Netherlands
- Apr 17, 2014Phase 1 study in Pharmacokinetic InteractionsNCT02124954 · 18 enrolled · United Kingdom
- Aug 20, 2014Phase 2 study in Elevated Lp(a)NCT02241772 · 42 enrolled · Denmark
- Aug 20, 2014Phase 1 study in DyslipidemiasNCT02241759 · 136 enrolled · United Kingdom
- Feb 25, 2015Phase 1 study in DyslipidemiasNCT02408055 · 6 enrolled · United Kingdom
- Aug 12, 2015Phase 1 study in DyslipidemiasNCT02523391 · 26 enrolled · United Kingdom
- Jun 9, 2016Named obicetrapibINNProposed as its International Nonproprietary Name in WHO's List 115 · before, TA-8995
TargetBeta
“Cholesteryl ester transfer protein inhibitor”ChEMBL 37, by rule
Studies
All 6 Xention leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02523391Dyslipidemias · United Kingdom | 1 | Completed | Nov 2015 | 26 |
| NCT02408055Dyslipidemias · United Kingdom | 1 | Completed | Aug 2015 | 6 |
| NCT02241772Elevated Lp(a) · Denmark | 2 | Completed | Jan 2015 | 42 |
| NCT02241759Dyslipidemias · United Kingdom | 1 | Completed | Nov 2014 | 136 |
| NCT02124954Pharmacokinetic Interactions · United Kingdom | 1 | Completed | Jul 2014 | 18 |
| NCT01970215Dyslipidemias · Denmark, Netherlands | 2 | Completed | Jul 2014 | 364 |
How it is read
Names in the registry
- “TA-8995”, 16 entries
- “Obicetrapib”, 11 entries
- “Obicetrapib 10 mg”, 2 entries
- “obicetrapib 10 mg + ezetimibe 10 mg FDC daily”, 2 entries
- “Obicetrapib 10mg”, 2 entries
Conditions, from the studies’ own filings
- Dyslipidemias, 10 studies
- Hypercholesterolemia, 4 studies
- Alzheimer Disease, 2 studies
- Hyperlipidemias, 2 studies
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.